391 related articles for article (PubMed ID: 9357101)
1. Antisense oligonucleotides: a new therapeutic approach.
Temsamani J; Guinot P
Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
[TBL] [Abstract][Full Text] [Related]
2. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
5. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
6. [Development of antisense nucleotides for therapy].
Wang J; Wang L; Wang Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Feb; 23(1):230-4. PubMed ID: 16532848
[TBL] [Abstract][Full Text] [Related]
7. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
Wagner A; Bock CT; Fechner H; Kurreck J
Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
[No Abstract] [Full Text] [Related]
8. Antisense oligonucleotides: towards clinical trials.
Agrawal S
Trends Biotechnol; 1996 Oct; 14(10):376-87. PubMed ID: 8987636
[TBL] [Abstract][Full Text] [Related]
9. Antisense anticancer oligonucleotide therapeutics.
Wang H; Prasad G; Buolamwini JK; Zhang R
Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical pharmacology of antisense oligonucleotides.
Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
[TBL] [Abstract][Full Text] [Related]
11. Antisense and/or immunostimulatory oligonucleotide therapeutics.
Agrawal S; Kandimalla ER
Curr Cancer Drug Targets; 2001 Nov; 1(3):197-209. PubMed ID: 12188879
[TBL] [Abstract][Full Text] [Related]
12. Locked nucleic acid holds promise in the treatment of cancer.
Frieden M; Ørum H
Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
14. Antisense has growing pains.
Gura T
Science; 1995 Oct; 270(5236):575-7. PubMed ID: 7570012
[No Abstract] [Full Text] [Related]
15. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
17. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
18. DNA drug design for cancer therapy.
Cho-Chung YS
Curr Pharm Des; 2005; 11(22):2811-23. PubMed ID: 16101439
[TBL] [Abstract][Full Text] [Related]
19. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
Jepsen JS; Sørensen MD; Wengel J
Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]